Monday, May 29, 2023
Clinical Advances in Psoriasis
The treatment of psoriasis has advanced substantially due to therapies that target key immune pathways involved in disease pathophysiology. As the therapeutic options for psoriasis expand, members of the healthcare team need a better understanding of how to use various medications and where they can be most optimally used. Patients and clinicians have set their sights on clear skin and minimal disease impact on quality of life as treatment goals. Partnership and shared decision making are increasingly important to achieve these goals in the management of psoriasis.
Supported by an independent educational grant from
Ortho Dermatologics, a division of Bausch Health
Steering Committee Co-Chair
Professor
Chairman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Steering Committee Co-Chair
Chairman of Dermatology
Baylor University Medical Center Dallas
Dallas, Texas
Nurse Practitioner, Dermatology
VA Portland Healthcare System
Portland, Oregon
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support
Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair and Director, Clinical Trials and Outcomes Research
Director, Psoriasis Program
Department of Dermatology
Keck School of Medicine at USC
University of Southern California
Los Angeles, California
Professor
Chair
Department of Dermatology
University of Alabama at Birmingham
Professor
Chair
Program Director
Eastern Virginia Medical School
Norfolk, Virginia
Steering Committee Co-Chair
Mark G. Lebwohl, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Kadmon Holdings, Inc; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Vidac
Steering Committee Co-Chair
Alan Menter, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Allergan, Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Vitae; Xenoport
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Janssen Pharmaceuticals; LEO Pharma
Steering Committee Member
Lakshi Aldrege, MSN, ANP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; Sun Pharma
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; Sun Pharma
Steering Committee Member
April W. Armstrong, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Modernizing Medicine; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Science 37
Received grants for clinical research from: AbbVie Inc.; Dermira Inc.; Janssen Pharmaceuticals; LEO Pharma; Lilly; Modernizing Medicine; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.
Steering Committee Member
Boni Elewski, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Valeant
Received grants for clinical research from: AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Incyte Corporation; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sun Pharmaceutical Industries Ltd.; Viamet Pharmaceuticals, Inc.; Valeant
Steering Committee Member
Abby S. Van Voorhees, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Allergan, Inc.; Celgene Corporation; Dermira, Inc; Novartis Pharmaceuticals Corporation; Valeant
Other: Merck & Co., Inc.